Home » Stocks » Blueprint Medicines

Blueprint Medicines Corporation (BPMC)

Stock Price: $74.45 USD -0.18 (-0.24%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.12B
Revenue (ttm) 75.18M
Net Income (ttm) -395.04M
Shares Out 55.27M
EPS (ttm) -7.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $74.45
Previous Close $74.63
Change ($) -0.18
Change (%) -0.24%
Day's Open 74.28
Day's Range 74.00 - 76.16
Day's Volume 205,658
52-Week Range 43.29 - 93.90

More Stats

Market Cap 4.12B
Enterprise Value 3.68B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 55.27M
Float 54.64M
EPS (basic) -7.65
EPS (diluted) -7.70
FCF / Share -6.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.20M
Short Ratio 7.50
Short % of Float 8.88%
Beta 1.01
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 54.73
PB Ratio 7.10
Revenue 75.18M
Operating Income -406.03M
Net Income -395.04M
Free Cash Flow -339.63M
Net Cash 433.82M
Net Cash / Share 7.85
Gross Margin -352.40%
Operating Margin -540.07%
Profit Margin -525.40%
FCF Margin -451.74%
ROA -31.24%
ROE -67.29%
ROIC -72.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (15)

Buy 12
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(30.77% upside)
Current: $74.45
Target: 97.36
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth49.39%107.79%-22.85%143.61%---
Gross Profit66.5144.5221.4327.7711.40--
Operating Income-361-247-151-72.58-51.64-39.73-21.00
Net Income-348-237-148-72.50-52.77-40.29-20.91
Shares Outstanding47.8343.8737.7927.4918.241.421.02
Earnings Per Share-7.27-5.39-3.92-2.64-3.07-32.41-23.43
Operating Cash Flow-278-175-120-24.51-31.68-35.40-19.03
Capital Expenditures-14.01-12.68-15.51-2.35-4.88-0.70-0.26
Free Cash Flow-292-188-135-26.87-36.56-36.10-19.28
Cash & Equivalents48949967821516447.432.18
Total Debt95.95-1.524.077.349.042.86
Net Cash / Debt39349967621115738.39-0.69
Book Value464419624213144-79.38-41.45
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Blueprint Medicines Corporation
Country United States
Employees 419
CEO Jeffrey W. Albers

Stock Information

Ticker Symbol BPMC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BPMC
IPO Date April 30, 2015


Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.